183 related articles for article (PubMed ID: 21281839)
1. The economics of diabetes prevention.
Herman WH
Med Clin North Am; 2011 Mar; 95(2):373-84, viii. PubMed ID: 21281839
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.
Ann Intern Med; 2005 Mar; 142(5):I28. PubMed ID: 15738446
[No Abstract] [Full Text] [Related]
4. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group
Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
[TBL] [Abstract][Full Text] [Related]
5. Economics of diabetes-cost impact of not treating diabetes early and intensively.
Cefalu W
Clin Cornerstone; 2004; 6(2):51-60. PubMed ID: 15628693
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study.
Liu X; Li C; Gong H; Cui Z; Fan L; Yu W; Zhang C; Ma J
BMC Public Health; 2013 Aug; 13():729. PubMed ID: 23919839
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Eddy DM; Schlessinger L; Kahn R
Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
Bertram MY; Lim SS; Barendregt JJ; Vos T
Diabetologia; 2010 May; 53(5):875-81. PubMed ID: 20135088
[TBL] [Abstract][Full Text] [Related]
10. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
12. Economics of type 2 diabetes prevention.
Kissimova-Skarbek K
Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
[No Abstract] [Full Text] [Related]
13. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.
Hernan WH; Brandle M; Zhang P; Williamson DF; Matulik MJ; Ratner RE; Lachin JM; Engelgau MM;
Diabetes Care; 2003 Jan; 26(1):36-47. PubMed ID: 12502656
[TBL] [Abstract][Full Text] [Related]
15. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance.
Josse RG; McGuire AJ; Saal GB
Int J Clin Pract; 2006 Jul; 60(7):847-55. PubMed ID: 16858756
[TBL] [Abstract][Full Text] [Related]
16. Prevention of diabetes: a strategic approach for individual patients.
Shin JA; Lee JH; Kim HS; Choi YH; Cho JH; Yoon KH
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():79-84. PubMed ID: 23280871
[TBL] [Abstract][Full Text] [Related]
17. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions.
Stevens JW; Khunti K; Harvey R; Johnson M; Preston L; Woods HB; Davies M; Goyder E
Diabetes Res Clin Pract; 2015 Mar; 107(3):320-31. PubMed ID: 25638454
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.
Olchanski N; van Klaveren D; Cohen JT; Wong JB; Ruthazer R; Kent DM
Acta Diabetol; 2021 Jun; 58(6):707-722. PubMed ID: 33517494
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes.
Thomas GN; Jiang CQ; Taheri S; Xiao ZH; Tomlinson B; Cheung BM; Lam TH; Barnett AH; Cheng KK
Curr Diabetes Rev; 2010 Nov; 6(6):378-87. PubMed ID: 20879973
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
